title: Antimicrobial activity of a new synthetic peptide loaded in polylactic acid or poly(lactic-co-glycolic) acid nanoparticles against Pseudomonas aeruginosa, Escherichia coli O157:H7 and methicillin resistant Staphylococcus aureus (MRSA).
abstract: Nanocarrier systems are currently being developed for peptide, protein and gene delivery to protect them in the blood circulation and in the gastrointestinal tract. Polylactic acid (PLA) and poly(lactic-co-glycolic) acid (PLGA) nanoparticles loaded with a new antimicrobial GIBIM-P5S9K peptide were obtained by the double emulsion solvent extraction/evaporation method. PLA- and PLGA-NPs were spherical with sizes between 300 and 400 nm for PLA and 200 and 300 nm for PLGA and <0.3 polydispersity index as determined by dynamic light scattering and scanning electron microscopy), having the zeta potential of >20 mV. The peptide-loading efficiency of PLA-NP and PLGA-NPs was 75% and 55%, respectively. PLA- and PLGA-NPs released around 50% of this peptide over 8 h. In 10% human sera the size of peptide loaded PLA- and PLGA-NPs increased between 25.2% and 39.3%, the PDI changed from 3.2 to 5.1 and the surface charge from -7.15 to 14.6 mV. Both peptide loaded PLA- and PLGA-NPs at 0.5 μM peptide concentration inhibited the growth of Escherichia coli O157:H7 (E. coli O157:H7), methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas. aeruginosa (P. aeruginosa). In contrast, free peptide inhibited at 10 μM but did not inhibit at 0.5 and 1 μM. These PLA- and PLGA-NPs presented <10% hemolysis indicating that they are hemocompatible and promising for delivery and protection system of GIBIM-P5S9K peptide.
authors.affiliation: Escuela de Química, Facultad de Ciencias, Universidad Industrial de Santander, Cra 27 # calle 9 (CP680002) Bucaramanga, Colombia. Departamento de Química, Universidad Nacional de Colombia, Cra 30 # 45-03, 111321 Bogotá, Colombia.
authors.forename: J
authors.initials: J
authors.lastname: Cruz
authors.forename: J
authors.initials: J
authors.lastname: Flórez
authors.forename: R
authors.initials: R
authors.lastname: Torres
authors.forename: M
authors.initials: M
authors.lastname: Urquiza
authors.forename: J A
authors.initials: JA
authors.lastname: Gutiérrez
authors.forename: F
authors.initials: F
authors.lastname: Guzmán
authors.forename: C C
authors.initials: CC
authors.lastname: Ortiz
mesh_terms: D000595:Amino Acid Sequence; D000890:Anti-Infective Agents / Q000494:pharmacology*; D065546:Drug Liberation; D019453:Escherichia coli O157 / Q000187:drug effects*; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D019344:Lactic Acid / Q000737:chemistry*; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D010316:Particle Size; D010455:Peptides / Q000737:chemistry / Q000494:pharmacology*; D011091:Polyesters / Q000737:chemistry; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D044967:Serum / Q000378:metabolism
chemical_list: D000890:Anti-Infective Agents; D010455:Peptides; D011091:Polyesters; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; C033616:poly(lactide)